OBJECTIVES:  To assess the clinical burden, health care utilization, and cost patterns of prostate cancer patients in the US veteran population. METHODS:  Patients diagnosed with prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification code: 185.xx) were selected from the Veterans Health Administration (VHA) database (October 1, 2010-September 30, 2014). The first observed diagnosis date was defined as the index date. Continuous medical and pharmacy benefits were required 12 months pre- and post-index date. The 10 most common comorbidities were calculated for the 12-month baseline period. The 10 most commonly prescribed medications were calculated for 60 days post-index date. Health care resource utilization (inpatient, outpatient, pharmacy) and costs (inpatient, outpatient, pharmacy, total) were assessed for the 12-month follow-up period. Descriptive statistics were calculated as means ± standard deviation (SD) and percentages to measure treatment, cost, and utilization distribution in the sample. RESULTS:  Among all study patients diagnosed with prostate cancer (n=195,989), the most common comorbidities were hypertension (24.24%), elevated prostate-specific antigen (PSA) levels (22.26%), diabetes (13.96%), bilateral hearing loss (8.19%), and hyperlipidemia (7.95%). The most commonly prescribed medications for prostate cancer patients were simvastatin (16.95%), lisinopril (14.62%), omeprazole (13.43%), amlodipine besylate (11.05%), and hydrochlorothiazide (7.56%). The percentage of patients with inpatient stays (12.24%), outpatient visits (99.88%), and pharmacy visits (85.26%) were calculated. Prostate cancer patients incurred $4,488 (SD=$27,143) in inpatient, $8,690 (SD=$13,923) in outpatient visit, and $1,296 (SD=$4,839) in pharmacy costs. Total expenditures were $14,474 (SD=$34,318). CONCLUSIONS:  Results suggest that hypertension and elevated PSA levels were the most common comorbidities among prostate cancer patients. This disease is associated with high outpatient visit utilization, resulting in a high cost burden.